The agreement also settles the patent litigation relating to Barr’s generic version of the drug which its subsidiary Duramed Pharmaceuticals markets under the name Kariva.
The deal includes rights to the US marketing approval for the drug which is available in a 28-tablet regimen that represents a combination of desogestrel/ethinyl estradiol and ethinyl estradiol.
Barr currently manufactures and markets over 70 different generic pharmaceutical products, including 22 oral contraceptive products, representing the largest category of the company’s generic portfolio, and 17 proprietary pharmaceutical products, largely concentrated in the female healthcare arena.
Organon recently announced that it has entered into a research collaboration with Keel Pharmaceuticals to discover and develop novel biotherapeutics based on approaches and targets identified by Keel, a company that focuses on developing treatments for type one diabetes and other autoimmune diseases.